In the new European Union (EU) policy for the Registration, Evaluation and Authorisation of Chemicals (REACH), the European Commission (EC) proposes that 30,000 existing chemicals should be evaluated within a period of 15 years. Data on the hazardous properties of chemicals must be provided by industry, which must also cover the costs, if additional testing is required. There is agreement within the EC that additional toxicity testing should in the first place rely on non-animal in silico predictions and in vitro tests, for both financial and animal welfare reasons. To put the REACH policy into a realistic perspective, advisers to national governments of the EU Member States, from the EU Commission and industry have published estimates on the cost of the additional testing which is likely to be necessary. Assuming a worst case scenario, in which all the existing chemicals will have to be tested in vivo for all the required endpoints, more than 50 million test animals may have to be used, and reproductive toxicology will account for up to 70% of them. 1 The REACH system represents an attempt to increase safety from the effects of chemicals, both for humans and for the environment, by filling gaps in knowledge on the toxic properties of new chemicals and existing chemicals (i.e. those in use before 1982, when the current regulations for new chemicals came into force). For historical reasons, the spectrum of reproductive toxicity testing is markedly different for drugs and for chemicals. In drug development, during preclinical testing, "segment 1, 2 and 3" studies have to be conducted, which cover pregnancy, as well as pre-natal and post-natal toxicity, and also the lactation period. In contrast, the regulatory testing requirements for industrial chemicals mainly depend on the production volume. These include two types of reproductive toxicity test: a developmental toxicity study, and a one-generation or two-generation "fertility" study. Under the proposed REACH legislation, these studies will have to be conducted for the 10,000 chemicals with an annual production volume of more than 10 tonnes. 1 From the animal welfare perspective, and also from a scientific and economical standpoint, we must ask whether the world would really be a safer place after two-generation studies had been conducted for 30% of the existing chemicals. The clear answer is no, for the following reasons:
1. The predictive value of animal tests for human pregnancy is poor, according, for example, to a recent analysis by Bailey and co-workers, entitled "The Future of Teratology is In Vitro". 2 2. Epidemiological data on the outcome of human pregnancy for women who have been exposed to specific drugs, shows that only 2% of malformations can be attributed to drugs and other chemicals. Thus, with a few exceptions, the human embryo seems to be more resistant to toxic chemicals than the embryos of laboratory animals. 3 3. It must be borne in mind that the chemicals used in drugs and pesticides are designed to interact with active molecules at the cellular level in the human body and in the pest species, respectively. In contrast, industrial chemicals are designed to improve the functions of chemical products for quite different purposes, often as a result of their physical properties, rather than their chemical reactivity. Thus, in contrast to drugs and pesticides, a large proportion of industrial chemicals are not toxic to reproduction.
4. This assumption is substantiated by experience obtained with more than 3000 new chemicals in the EU during the past 20 years, since only a few of these chemicals have been classified and labelled as toxic to reproduction.
5.
There is no substantial evidence to prove a correlation between the adverse effects observed in two-generation studies in rodents and human reproduction and fertility.
6. When the two-generation study was introduced as an OECD Test Guideline in 1982, the test was not formally validated with respect to its relevance for human reproduction and fertility.
Thus, while reproductive toxicology seems to have the greatest implications within the REACH policy in terms of the economic cost of testing and the numbers of animals that will have to be used, it certainly does not deserve this high priority when viewed from a scientific perspective. A short look back on the history of regulatory toxicology leads to the Thalidomide disaster, when, in 1960, severely malformed children were born to moth-Editorial REACH Testing Requirements Must Not be Driven by Reproductive Toxicity Testing in Animals ers who had taken this drug during pregnancy. During its development, the drug had not undergone any testing in pregnant animals, so, as a seemingly appropriate reaction, governments around the world introduced stricter legislation on preclinical drug testing, in an attempt to ensure drug safety for humans, including unborn children. During the next decade, regulatory toxicology was dominated by embryotoxicity testing, and later, by fertility testing as well. Since no major side-effects were found, the principal focus of toxicity testing shifted from reproductive toxicity to carcinogenicity and mutagenicity testing, and more recently, to molecular toxicology. As a consequence, toxicologists in industry and regulatory agencies lost interest in reproductive toxicology, which is still based on the application of gross morphological endpoints for risk assessment, and does not yet involve molecular markers of development.
Taking all this into account, it is surprising that, due to the formal requirements of the new REACH policy, interest in reproductive toxicity testing is undergoing a kind of Renaissance. The regulators, who are currently discussing the issue with colleagues from industry within the REACH Implementation Procedure (RIP), tend to adhere formally to the legislation rather than to criticise it. They always use the most simple and the most conservative approach. Thus, when they are asked, what kind of information they would prefer for risk assessment, these regulators will try to get as much information as possible. So, as long as industrial toxicologists will provide them with the results of two-generation studies, they will always ask for them. As a consequence, there is no pressure on regulators or industry to take initiatives to reduce reproductive toxicity testing in vivo when implementing the REACH policy.
From the scientific point of view, this scenario is unacceptable, since according to EU Directive 86/609/EEC for the protection of laboratory animals, a toxicity test in animals must only be conducted if the information cannot be obtained by any other means. If scientists in industry propose to conduct two-generation studies, they should be required to provide scientific evidence that the ultimate goal of "classification and labelling" of a reproductive toxicant could only be achieved if a two-generation study was conducted. The experts working on the implementation of the REACH policy therefore have a duty to develop strategies for deciding when reproductive toxicity testing in animals is necessary and should be permitted. At present, the decision to stop further testing and to proceed to classification and labelling, rather than to proceed to conducting a two-generation study, relies on "expert judgement". The REACH policy is to promote "intelligent testing strategies" and "integrated testing". However, so long as the "experts" involved in executing the REACH policy at the national level are not participating in establishing the "intelligent testing strategies" for repro-ductive toxicity testing, the REACH policy will require much more testing in animals than is acceptable from either a scientific or an animal welfare perspective.
Up to now, no guidance has been developed on how to use the information from in vitro toxicity testing and QSAR predictions for regulatory purposes. The advocates of the continuation of animal toxicity testing have a simplistic view of the current situation. They claim, for example, that in vitro embryotoxicity testing is useless, even if the tests have successfully been validated as capable of distinguishing between chemicals which are/are not likely to be embryotoxic, since the results will always trigger further testing in vivo, for the following reasons: if the results are positive, they have to be confirmed by an in vivo animal study, and if the results are negative, they must be confirmed in vivo, in order to verify the safety of the chemical. Thus, in vitro studies are both useless and a waste of time, since they always have to be confirmed in an animal study. This is the reality today, although the EC's REACH policy proposals ask for the use of in vitro data in the first place, for classification and labelling, as well as for risk assessment.
This example clearly illustrates the divergent positions of the EC Commission on the one side, and the regulators and industry in the EU Member Sates on the other side. Since there is still time for improvement, toxicologists should have the courage to take action and insist on the introduction of genuine "intelligent testing strategies" into the REACH policy, in order to reduce reproductive toxicity testing in vivo to the absolute minimum. Ultimately, human interests and the environment in general can only be protected by the skilful development and rigorous application of sound scientific principles and procedures, as a basis for both hazard prediction and risk assessment.
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